Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

Trial Profile

A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Dasiglucagon (Primary)
  • Indications Congenital hyperinsulinism
  • Focus Registrational; Therapeutic Use
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 08 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 24 Dec 2018 Status changed from planning to not yet recruiting.
    • 15 Nov 2018 According to a Zealand Pharma media release, the company expects to initiate this trial in Q4 2018, which is slightly later than the earlier announcement as the company is incorporating additional comments from FDA to simplify and improve the program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top